# Single and Multiple Ascending Dose Study of TD-8236 by Inhalation

> **NCT03652038** · PHASE1 · COMPLETED · sponsor: **Theravance Biopharma** · enrollment: 94 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** TD-8236
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03652038
- **Lead sponsor:** Theravance Biopharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-11-07
- **Primary completion:** 2020-07-13
- **Final completion:** 2020-07-13
- **Target enrollment:** 94 (ACTUAL)
- **Last updated:** 2021-09-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03652038

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03652038, "Single and Multiple Ascending Dose Study of TD-8236 by Inhalation". Retrieved via AI Analytics 2026-09-21 from https://api.ai-analytics.org/clinical/NCT03652038. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*